In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers
- 120 Downloads
The present study involved the in vivo evaluation of orally administered guar gum-based colon-targeted tablet formulations of celecoxib (colon-targeted tablet-20 or colon-targeted tablet-30) as compared with an immediate release capsule in 15 human volunteers. Blood samples were obtained at different time intervals and the plasma concentration of celecoxib was estimated by reversed phase HPLC. The immediate release capsules of celecoxib might have disintegrated very fast in GI tract and absorbed quickly from stomach and small intestine thereby producing peak plasma concentration (Cmax of 478±57 ng/ml) within 3.8±0.1 h (Tmax). Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8h resulting in peak concentration (Cmax) of 78±6ng/ml or 88±15ng/ml at 10.5±1.9 h or 13.5±1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478±57 ng/ml at 3.8±0.1h (Tmax). Colon-targeted tablets showed decreased AUC0–∞, Cmax and absorption rate constant, prolonged absorption time (ta), and increased t1/2 in comparison with the immediate release capsules. The results of the study indicated that the guar gum-based colon-targeted tablets of celecoxib did not release the drug significantly in stomach and small intestine, but delivered to the colon resulting in a slow absorption of the drug and making it available for local action in the colon.
KeywordsCelecoxib Colon-targeted tablets Guar gum In vivo evaluation
Unable to display preview. Download preview PDF.
- 8.Needleman P., Isakson P.C. (1998): Selective inhibition of cyclooxygenase-2. Science and Medicine., 1, 26–35.Google Scholar
- 11.Gibaldi M., Perrier, D. (1990): Pharmacokinetics, 2nd edition, Marcel Dekker, New York.Google Scholar
- 12.Ritschel W.A. (1986): UC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis. Methods and findings of Experimental Clinical Pharmacology. 8: 633–640.Google Scholar
- 19.Krishnaiah Y.S.R., Indira Muzib Y., Srinivasa Rao G. et al. (2002). Design and In vitro evaluation of oral colon targeted drug delivery systems for tinidazole. J. Drug Target., (accepted).Google Scholar
- 20.Grahnen A. (1984): Design of bioavailability studies. Pharm. Int., 5, 100–103.Google Scholar
- 21.Westlake W.J. (1988) In: K.E. Peace (ed.), Biopharmaceutical statistics for drug development, Marcel Dekker, New York, 329.Google Scholar
- 22.RobertsII L.J., Morrow J.D. (2001): Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics (10th edition), McGraw Hill, Medical Publishing Division, New York, 715.Google Scholar